Group Health Cooperative of Puget Sound

Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 Accessions New Publication Demonstrates OVA1 Superiority to Standard of Care Expanded Access of OVA1 Through AIM Specialty Health Conference Call and Webcast Today at 4:30 p.m. ET AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended, June 30, 2021. “We are pleased with the volume growth in our products as the economy has somewhat emerged from COVID-19 restriction as well as with the advancement of our preparations for our fourth quarter 2021 launch of OVASight,” indicated Valerie Palmieri, Chief Executive Officer. “We are making positive progress on our product collaboration with the Dana Farber Cancer Institute as we disclosed in the first quarter of 2021. We have also continued to have a positive dialogue with the FDA regarding our planned EndoCheck product.” Recent Corporate Highlights Capital Resources Financial Highlights Highlights Second Quarter 2021 vs. Second Quarter 2020: Highlights of Second Quarter 2021 vs. First Quarter 2021: Conference Call and WebcastAspira will host a call today at 4:30 p.m. Eastern Time to discuss results followed by a question-and-answer period. About Aspira Women’s Health Inc.Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.  Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plusTM combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiXTM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVASightTM and EndoCheckTM. Visit our website for more information at . Forward-Looking StatementsThis press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding anticipated expenses. These statements involve a number of risks and uncertainties.  All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in Aspira’s Annual Report on Form 10-K for the year ended December 31, 2020. The events and circumstances reflected in Aspira’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.  Aspira expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLCTel 617-535-7742

AUSTIN, Texas, June 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease, released the analytical and initial clinical data for OVASight™ in an abstract titled “Serum-based Assay for Adnexal Mass Risk of Ovarian Malignancy”. Registrants attending the American Society of Clinical Oncology (“ASCO”) 2021 virtual meeting gained access to the poster on May 19, 2021, and the on-demand presentation will be released to the ASCO virtual meeting registrants at 9:00 a.m. EDT on June 4, 2021. OVASight (MIA3G) is third-generation OVA technology and is a laboratory-developed, blood-based pelvic mass risk assessment test for ovarian cancer in a low prevalence population. It was developed to increase specificity, maintain high sensitivity with early-stage disease, and allow for conservative management of women with a suspected benign mass. A total of 596 samples collected from real-world patients were used to validate the OVASight diagnostic algorithm. Validation data demonstrated 89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6% in a low prevalence population (3.8%). In addition, overall sensitivity as well as sensitivity in early-stage disease were significantly better than CA-125 alone. See table below: “Based on this promising data, we are thrilled with the performance of this new test,” stated Elena Ratner, M.D., Global Chief Global Medical Advisor, Clinical and Translational Medicine at Aspira Women’s Health. Dr. Ratner further explained that “it is important to give providers better tools to help provide personalized risk assessment for women with pelvic masses and expectant management for those masses that are most likely benign.” Below are details of the abstract accepted at ASCO. All posters will be available to ASCO 2021 virtual meeting registrants on-demand beginning at 9:00 a.m. EDT on June 4, 2021. About Aspira Women’s Health Inc.Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. The next generation of products in development are OVASight™ and EndoCheck™. Visit our website for more information at . Investor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com

AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest private Healthcare Provider in New York State, today announced the start of a prospective Clinical Study for Ovarian Cancer Risk Detection. Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians. The study will enroll over 600 prospective women with adnexal masses. The study will also enroll over 2000 women at high risk for Ovarian Cancer, either due to a personal or family history of cancer or are carriers of a germline variant associated with hereditary breast and ovarian cancer syndrome. Ovarian cancer risk will be assessed by both CA125 and Aspira’s OVASight proprietary algorithm. The primary objective is to increase our total trial enrollment to validate the serial monitoring aspect of the OVASight algorithm in women who present with an adnexal mass. The secondary endpoint is to test additional genomic markers to develop a proteogenomic test for early-stage detection of ovarian cancer. This study will support and collect different biological targets and clinical data metrics to support our innovation pipeline for test development of early diagnosis of ovarian, and other gynecological cancers. “Having testing options for women with benign masses to monitor them over time, as well as having a solution for assessing risk in high-risk women will provide meaningful insights for providers treating these women,” said Elena Ratner, MD, Gynecologic Oncologist and Global Chief Medical Advisor, Clinical and Translational Medicine “Northwell Health is proud to work with Aspira on this important clinical study,” stated the Principal Investigator of the trial, Dr. Gary L. Goldberg, Vice Chair for Research, Department of Obstetrics and Gynecology, at Northwell Health and researcher at the Feinstein Institutes. “As clinicians we need innovative and reliable testing options for women and our hope is this study will provide key insights for diagnosing and treating women who are high risk for developing ovarian cancer.” Aspira Women’s Health has over 10 years of experience developing Ovarian Cancer Risk Assessment tests with its proprietary, FDA-Cleared OVA1® and OVERA® multivariate index assay’s. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender-specific cancer with an over 50 percent mortality rate impacting women of all ages and ethnicities. “This study is twofold, one is to vastly increase our enrollment to clinically validate the serial monitoring aspect OVASight test for all women who present with a mass and hereditary breast and ovarian cancer syndrome, and second, enrich our research and innovation pipeline,” said Lesley Northrop, PhD, FACMG, Chief Scientific Officer, Aspira Women’s Health. “I am incredibly excited to work with the Feinstein Institutes in enhancing our biobank of biological samples and clinical data metrics. This will allow us the ability to evaluate additional biomarkers including ctDNA, RNA and proteins to apply as a multi-modal approach in early diagnosis of ovarian cancer as a liquid-biopsy based test.” About the Feinstein Institutes The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. About Aspira Women’s Health Inc.Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVASightTM and EndoCheckTM. Visit our website for more information at . Investor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com